Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
105,357,143
-
Total 13F shares
-
88,633,130
-
Share change
-
+5,945,279
-
Total reported value
-
$665,700,838
-
Put/Call ratio
-
7.2%
-
Price per share
-
$7.51
-
Number of holders
-
140
-
Value change
-
+$50,617,366
-
Number of buys
-
71
-
Number of sells
-
55
Institutional Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) as of Q3 2025
As of 30 Sep 2025,
Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) was held by
140 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
88,633,130 shares.
The largest 10 holders included
Soleus Capital Management, L.P., MORGAN STANLEY, ORBIMED ADVISORS LLC, Deep Track Capital, LP, Vivo Capital, LLC, Commodore Capital LP, BlackRock, Inc., VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., and Candriam S.C.A..
This page lists
140
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.